Mucormycosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032


 Mucormycosis is caused by the fungi belonging to the order Mucorales. Humans acquire the infection predominantly by inhalation of sporangiospores, occasionally by ingestion of contaminated food or traumatic inoculation. The fungi under Mucorales are ubiquitous and morphologically appear as broad, aseptate, or sparsely septate ribbon-like hyphae. Rhizopus arrhizus is the most common agent causing mucormycosis across the globe, followed by Lichtheimia, Apophysomyces, Rhizomucor, Mucor, and Cunninghamella species. Mucormycosis is associated with angio-invasion and high mortality. The infection is increasingly reported in patients with diabetes mellitus, hematological malignancy, solid organ transplants, and corticosteroid therapy.

·       Mucormycosis is associated with a high risk of mortality in 54% to 71% of patients, with mortality depending on body site infected, fungus type, and the patient’s overall condition

·       COVID-19-associated mucormycosis (CAM) is evident in the second wave of COVID-19 in the ASIAN population with an incidence rate of 0.64 to 1.2 cases per 100,000 hospitalized patients.

Thelansis’s “Mucormycosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Mucormycosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Mucormycosis across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Mucormycosis Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Mucormycosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033